ALNY must really be hurting to be holding an investor CC for the results of a phase-1 trial.
Normally I would agree but they are trying hard to validate that RNAi is legit and that delivery is feasible, given the bearish view on RNAi, so any actual clinical data that's a step in this direction is presumably important to talk about.
Market Data 
Markets 
AI
